FDA Accepts Supplement for ADEMPAS (Riociguat) by Bayer Healthcare
The FDA has accepted a supplemental application for ADEMPAS (Riociguat) from Bayer Healthcare.
Published: July 14, 2026
Updated: July 14, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Pulmonary Hypertension
Company: Bayer
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Bayer
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for ADEMPAS signifies a potential enhancement of Bayer's competitive position in the pulmonary hypertension market. This could lead to shifts in market dynamics, necessitating close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for updates on the review process and any subsequent approval outcomes.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.